Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh

Vaccine. 2023 May 5;41(19):3137-3140. doi: 10.1016/j.vaccine.2023.04.014. Epub 2023 Apr 13.

Abstract

A cluster-randomized trial of Vi-TT was conducted in Dhaka, Bangladesh, using JE vaccine as the control. A subset of 1,500 children were randomly selected on 2:1 basis (Vi-TT vs JE) to assess immune response. Blood was collected before vaccination, and on days 28, 545 and 730 post-vaccination and plasma anti-Vi-IgG response was measured. A robust, persistent antibody response was induced after single dose of Vi-TT, even after 2 years of vaccination. While there is no accepted serological antibody threshold of protection, analyzing the antibodies of children who received Vi-TT provides evidence that may later be useful in predicting population protection.

Keywords: Bangladeshi children; CRT-TCV; Long-term immune response.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Bacterial
  • Antibody Formation
  • Bangladesh
  • Child
  • Humans
  • Immunoglobulin G
  • Salmonella typhi
  • Tetanus Toxoid
  • Typhoid Fever* / prevention & control
  • Typhoid-Paratyphoid Vaccines*
  • Vaccination
  • Vaccines, Conjugate

Substances

  • Tetanus Toxoid
  • Vaccines, Conjugate
  • Immunoglobulin G
  • Typhoid-Paratyphoid Vaccines
  • Antibodies, Bacterial